Collaborative work on evaluation of ovarian toxicity 3) Effects of 2- or 4- week repeated-dose toxicity and fertility studies with tamoxifen in female rats

Journal of Toxicological Sciences

Volumn 34, Issue 1 SPEC. ISS., 2009, Pages

  Tsujioka, Shigeharu ^a   Ban, Yoshiki ^a   Wise, L David ^b   Tsuchiya, Takayuki ^a   Sato, Takahiro ^a   Matsue, Kenta ^a   Ikeda, Takanori ^a   Sasak, Minoru ^a   Nishikibe, Masaru ^a  

^a Banyu Pharmaceutical Co   (Japan)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Female fertility; Ovarian toxicity; Rat; Tamoxifen

Indexed keywords

TAMOXIFEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COITUS; CONTROLLED STUDY; CORPUS LUTEUM; ESTROGEN ACTIVITY; ESTRUS CYCLE; FEMALE; FEMALE FERTILITY; FEMALE GENITAL SYSTEM; FOOD INTAKE; HISTOPATHOLOGY; INTERSTITIUM; MICROSCOPY; NONHUMAN; OVARY; OVARY FOLLICLE ATRESIA; PREGNANCY; RAT; REPRODUCTIVE TOXICITY; UTERUS; VAGINA; WEIGHT GAIN; ANIMAL; BODY WEIGHT; DRUG ADMINISTRATION; DRUG EFFECT; EATING; FERTILITY; HEALTH CARE ORGANIZATION; JAPAN; LONGEVITY; MALE; METABOLISM; METHODOLOGY; ORAL DRUG ADMINISTRATION; ORGAN SIZE; OVARY FOLLICLE; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TOXICITY TESTING; WISTAR RAT;

RATTUS; RODENTIA;

ADMINISTRATION, ORAL; ANIMALS; BODY WEIGHT; DRUG ADMINISTRATION SCHEDULE; EATING; ESTROUS CYCLE; FEMALE; FERTILITY; JAPAN; LONGEVITY; MALE; ORGAN SIZE; OVARIAN FOLLICLE; OVARY; PREGNANCY; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SOCIETIES, SCIENTIFIC; TAMOXIFEN; TOXICITY TESTS; UTERUS; VAGINA;

EID: 64949154319     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.34.s43     Document Type: Article

References (23)

1. Brown, A.P., Morrissey, R.L., Crowell, J.A. and Levine, B.S. (1999): Difluoromethylornithine in combination with tamoxifen in female rats: 13-week oral toxicity study. Cancer Chemother. Pharmacol., 44, 475-483.
2. Cho, S.D., Kim, J.H., Kim, D.Y., Lee, Y.S. and Kang, K.S. (2003): Pre-validation study for OECD enhanced test guideline 407 protocol by gavage for 4 weeks using propylthiouracil and tamoxifen. Toxicol. Lett., 144, 195-204.
3. Dao, B., Vanage, G., Marshall, A., Bardin, C.W. and Koide, S.S. (1996): Anti-implantation activity of antiestrogens and mifepristone. Contraception, 54, 253-258.
4. Davis, J.B., Dixon D. and Herbert, A.R. (1999): Ovary, Oviduct, Uterus, Cervix and Vagina. In Pathology of the Mouse (Maronpot, R.R., ed), pp.409-429, Cache River Press, Vienna.
5. Donath. J. and Nishino, Y. (1998): Effects of partial versus pure antiestrogens on ovulation and the pituitary-ovarian axis in the rat. J. Steroid Biochem. Mol. Biol., 66, 247-254.
6. Dunnett, C.W. (1964): New tables for multiple comparison with a control. Biometrics, 20, 482-492.
7. Ferland, L., Drouin, J. and Labrie, F. (1976): Role of sex steroids on LH and FSH secretion in the rat. Curr. Top. Mol. Endocri-nol., 3, 191-209.
8. Furr, B.J. and Jordan, V.C. (1984): The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther., 25, 127-205.
9. Harper, M.J. and Walpole, A.L. (1967): Mode of action of I.C.I. 46,474 in preventing implantation in rats. J. Endocrinol., 37, 83-92.
10. Hoyt, J.A., Fisher, L.F., Buelke-Sam, J.L. and Francis, P.C. (1998): The selective estrogen receptor modulator, raloxifene: reproductive assessments following premating exposure in female rats. Reprod. Toxicol., 12, 233-245.
11. Itskovitz. J. and Hodgen, G.D. (1988): Endocrine basis for the initiation, maintenance and termination of pregnancy in humans. Psychoneuroendocrinology, 13, 155-170.
12. Kaplan-Kraicer, R., Kostovetsky, I., Bardin, C.W. and Shalgi, R. (1996): Tamoxifen and RU39411 synergize with mifepristone to produce preimplantation pregnancy loss by increasing embryo transport (rat). Contraception, 53, 367-373.
13. Kennel, P., Pallen, C., Barale-Thomas, E., Espuna, G. and Bars, R. (2003): Tamoxifen: 28-day oral toxicity study in the rat basedon the Enhanced OECD Test Guideline 407 to detect endocrine effects. Arch. Toxicol., 77, 487-499.
14. Long, G.G., Cohen, I.R., Gries, C.L., Young, J.K., Francis, P.C. and Capen, C.C. (2001): Proliferative lesions of ovarian granulosa cells and reversible hormonal changes induced in rats by a selective estrogen receptor modulator. Toxicol. Pathol., 29, 719-726.
15. Matsuda, A., Higuchi, K., Karasawa, M., Yoneyama, S., Deguchi, J. and Miyamoto, M. (1997): Fourteen-day oral combination dose toxicity study of CGS 16949 A (aromatase inhibitor) with 5-fluorouracil or tamoxifen in rats. J. Toxicol. Sci., 22, 1-24.
16. Nephew, K.P., Osborne, E., Lubet, R.A., Grubbs, C.J. and Khan, S.A. (2000): Effects of oral administration of tamoxifen, toremifene, dehydroepiandrosterone, and vorozole on uterine histomorphology in the rat. Proc. Soc. Exp. Biol. Med., 223, 288-294.
17. Pedersen, T. and Peters, H. (1968): Proposal for a classification of oocytes and follicles in the mouse ovary. J. Reprod. Fertil., 17, 555-557.
18. Rodriguez, P., Fernandez-Galaz, C. and Tejero, A. (1993): Controlled neonatal exposure to estrogens: a suitable tool for reproductive aging studies in the female rat. Biol. Reprod., 49, 387-392.
19. Treinen, K.A., Rehm, S. and Wier, P.J. (1998): An evaluation of the novel selective estrogen receptor modulator, idoxifene, for effects on reproduction in rats and rabbits. Toxicol. Sci., 41, 199-207.
20. Tucker, M.J., Adam, H.K. and Patterson, J.S. (1984): Tamoxifen. In Safety Testing of New Drugs. Laboratory and Clinical Performance (D.R. Laurence, A.E.M. McLean, and M. Wetherall, ed), pp.125-161, Academic Press, London.
21. Tukey, J. W., Ciminera, J. L. and Heyse, J. F. (1985): Testing the statistical certainty of a response to increasing doses of a drug.Biometrics, 41, 295-301.
22. Yoshimura, I. (1987): In "Statistical analysis of toxicity and drug efficacy data", pp.28-35, Scientist Inc., Tokyo.
23. Yuan, Y.D. (1991): Female reproductive system. In Handbook of toxicologic pathology (Haschek, W.M., Rousseaux, C.G., ed), pp 891-931, Academic Press, San Diego.